Published in Ann Neurol on September 01, 2001
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci U S A (2006) 2.71
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat (2010) 2.29
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain (2012) 2.18
Genetic analysis of pathways to Parkinson disease. Neuron (2010) 2.15
Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol (2004) 1.90
The role of parkin in familial and sporadic Parkinson's disease. Mov Disord (2010) 1.90
Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx (2004) 1.77
The neuropathology of genetic Parkinson's disease. Mov Disord (2012) 1.73
The genetics of Parkinson disease. J Geriatr Psychiatry Neurol (2010) 1.69
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Multisystem Lewy body disease and the other parkinsonian disorders. Nat Genet (2015) 1.57
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56
How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep (2004) 1.54
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest (2003) 1.52
Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis (2009) 1.43
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med (2012) 1.30
Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell (2003) 1.23
Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx (2005) 1.22
Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity. Open Biol (2014) 1.19
Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol Neurobiol (2010) 1.13
Chasing genes in Alzheimer's and Parkinson's disease. Hum Genet (2004) 1.11
Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol (2008) 1.11
The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun (2013) 1.11
Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology (2009) 1.10
Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis (2011) 1.10
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Mol Neurodegener (2011) 1.05
Genetics and genomics of Parkinson's disease. Genome Med (2014) 1.04
Genetics of parkin-linked disease. Hum Genet (2004) 1.04
Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol (2012) 1.02
Copy number variation in familial Parkinson disease. PLoS One (2011) 1.02
Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination. Biochemistry (2011) 0.99
Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol (2013) 0.98
Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol (2012) 0.98
Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev (2009) 0.94
Parkin-dependent degradation of the F-box protein Fbw7β promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol Cell Biol (2013) 0.93
Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet (2008) 0.92
Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci (2008) 0.91
Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem (2016) 0.91
Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? Neurobiol Dis (2010) 0.88
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. Parkinsonism Relat Disord (2009) 0.87
Ubiquitin domain proteins in disease. BMC Biochem (2007) 0.86
Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample. Schizophr Res (2013) 0.86
A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci (2016) 0.86
Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. PLoS One (2016) 0.85
Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet (2015) 0.85
Parkin disease and the Lewy body conundrum. Mov Disord (2013) 0.84
Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation. Stem Cell Reports (2016) 0.83
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease. Cell Death Dis (2014) 0.82
Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance. PLoS One (2013) 0.82
Genetics of Parkinson disease. NeuroRx (2004) 0.82
Parkinson's disease. Subcell Biochem (2012) 0.82
Glycosylation of the sodium channel β4 subunit is developmentally regulated and involves in neuritic degeneration. Int J Biol Sci (2012) 0.82
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. Biomed Res Int (2014) 0.82
Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin. Hum Mutat (2015) 0.81
Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLoS One (2013) 0.81
HSPA1A-independent suppression of PARK2 C289G protein aggregation by human small heat shock proteins. Mol Cell Biol (2014) 0.80
Hematopoietic cytokines as therapeutic players in early stages Parkinson's disease. Front Aging Neurosci (2015) 0.78
Conserved role of dopamine in the modulation of behavior. Commun Integr Biol (2012) 0.78
Pathologic and therapeutic implications for the cell biology of parkin. Mol Cell Neurosci (2015) 0.78
Genetics of Parkinson's disease - a clinical perspective. J Mov Disord (2012) 0.78
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett (2015) 0.78
Postmortem studies in Parkinson's disease. Dialogues Clin Neurosci (2004) 0.78
Analyzing the roles of multi-functional proteins in cells: The case of arrestins and GRKs. Crit Rev Biochem Mol Biol (2015) 0.77
Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. BMC Neurol (2005) 0.77
Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD). Mol Brain (2016) 0.77
Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation. Mov Disord (2013) 0.77
A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics. Parkinsonism Relat Disord (2015) 0.76
Carnosic Acid Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells by Inducing Autophagy Through an Enhanced Interaction of Parkin and Beclin1. Mol Neurobiol (2016) 0.76
PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology? J Parkinsons Dis (2016) 0.76
Parkinson's Disease and Cognitive Impairment. Parkinsons Dis (2016) 0.75
Parkinson's disease: genetics and beyond. Curr Neuropharmacol (2007) 0.75
Parkin and Parkinson's: more than homonymy? Ann Neurol (2001) 0.75
In Silico Analysis of SNPs in PARK2 and PINK1 Genes That Potentially Cause Autosomal Recessive Parkinson Disease. Adv Bioinformatics (2016) 0.75
Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approach. Hum Genet (2016) 0.75
Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations. J Neurol (2006) 0.75
Olfaction in Parkin carriers in Chinese patients with Parkinson disease. Brain Behav (2017) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
UMLS concept indexing for production databases: a feasibility study. J Am Med Inform Assoc (2001) 9.02
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (1989) 7.03
Organization of heterogeneous scientific data using the EAV/CR representation. J Am Med Inform Assoc (1999) 6.97
How common are the "common" neurologic disorders? Neurology (2007) 6.77
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry (2007) 6.72
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet (2001) 6.67
Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med (2000) 6.27
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Parkinson disease in twins: an etiologic study. JAMA (1999) 5.45
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
SOR: project methodology. Br J Cancer (2001) 5.24
Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 5.14
PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. Mol Cell (1998) 4.82
Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage (2001) 4.48
GEM: a proposal for a more comprehensive guideline document model using XML. J Am Med Inform Assoc (2000) 4.46
Population requirement for primary hip-replacement surgery: a cross-sectional study. Lancet (1999) 4.29
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem (1995) 4.03
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol (1999) 3.99
Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 3.86
Nucleotide sequence of the papA gene encoding the Pap pilus subunit of human uropathogenic Escherichia coli. J Bacteriol (1984) 3.73
Prion dementia without characteristic pathology. Lancet (1990) 3.66
Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note. J Natl Cancer Inst (1969) 3.33
Audit of gonorrhoea test of cure at the genitourinary medicine department in Newcastle upon Tyne, UK. Int J STD AIDS (2003) 3.21
Deprivation and cause specific morbidity: evidence from the Somerset and Avon survey of health. BMJ (1996) 3.18
Verifying the stroke-free phenotype by structured telephone interview. Stroke (2000) 3.15
Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg (1969) 3.12
Cloning and sequencing of a Moraxella bovis pilin gene. J Bacteriol (1985) 3.10
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med (1983) 2.88
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
Primary structure of major outer membrane protein II (ompA protein) of Escherichia coli K-12. Proc Natl Acad Sci U S A (1980) 2.64
A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature (1993) 2.60
Primary structure of major outer membrane protein I of Escherichia coli B/r. Proc Natl Acad Sci U S A (1979) 2.60
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (1985) 2.58
The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med (1987) 2.58
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg (2000) 2.56
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
Early introduction of clinical skills teaching in a medical curriculum--factors affecting students' learning. Med Educ (2002) 2.46
Mirror movements in parkinsonism: evaluation of a new clinical sign. J Neurol Neurosurg Psychiatry (2005) 2.35
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology (2012) 2.34
Energy expended playing Xbox Kinect™ and Wii™ games: a preliminary study comparing single and multiplayer modes. Physiotherapy (2012) 2.34
Aetiology of Parkinson's disease. Lancet (1984) 2.32
Cell growth cycle block of T cell hybridomas upon activation with antigen. J Exp Med (1987) 2.30
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet (1998) 2.26
A full genome scan for late onset Alzheimer's disease. Hum Mol Genet (1999) 2.26
Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. Ann Neurol (1999) 2.26
Granulocytic sarcoma in childhood leukemia: imaging features. Radiology (1994) 2.26
Lower BMI cut-off value to define obesity in Hong Kong Chinese: an analysis based on body fat assessment by bioelectrical impedance. Br J Nutr (2001) 2.25
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci (1999) 2.25
A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant (2012) 2.25
Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods (2001) 2.22
Use of a nasal continuous positive airway pressure mask in the treatment of postoperative atelectasis in aortocoronary bypass surgery. Crit Care Med (1990) 2.21
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med (1998) 2.20
General practitioners' continuing education: a review of policies, strategies and effectiveness, and their implications for the future. Br J Gen Pract (1998) 2.20
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab (2009) 2.19
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. Neurology (2012) 2.18
Smoking and Parkinson's disease in twins. Neurology (2002) 2.15
Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A (1994) 2.14
Simultaneous bilateral laser in situ keratomileusis: safety and efficacy. Ophthalmology (1999) 2.13
The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging (1999) 2.11
The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med (1996) 2.11
alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet (2001) 2.07
The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP). Heart (2007) 2.06
Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus. Proc Natl Acad Sci U S A (1982) 2.06
Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology (2004) 2.05
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03